Observational analysis suggests immune-modulatory therapy improves outcomes in myasthenia gravis during COVID-19 infection.
Key Points
Immune-modulatory therapy may prevent permanent lung damage in myasthenia gravis patients with COVID-19, highlighting its importance.
A case involving a 46-year-old female with myasthenia gravis treated with 120mg pyridostigmine daily shows notable exacerbation during COVID-19 infection.
Analysis emphasizes the need for tailored therapy in myasthenia gravis patients experiencing SARS-CoV-2 infection.
This case report may prompt further research into optimal treatment strategies for myasthenia gravis in the context of viral infections.